Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 221.00
Bid: 221.00
Ask: 222.50
Change: -1.50 (-0.67%)
Spread: 1.50 (0.679%)
Open: 222.50
High: 225.00
Low: 219.00
Prev. Close: 222.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
5th Dec 20173:14 pmRNSIncrease of Holdings in Company
5th Dec 20177:00 amRNSPRTC's resTORbio Files IPO Registration Statement
4th Dec 20177:00 amRNSPureTech's Akili Pivotal ADHD Trial Successful
30th Nov 20177:00 amRNSPureTech's resTORbio Raises $40 Million
29th Nov 20177:00 amRNSPRTC's Vedanta Grows ImmunoOncology Collaborations
22nd Nov 20177:00 amRNSPureTech to Present at Piper Jaffray Conference
20th Nov 20177:00 amRNSPRTC's Clinical-Stage Anti-Aging Compound Advances
9th Nov 20177:00 amRNSPRTC to Present at Jefferies 2017 in London
3rd Nov 20177:00 amRNSPRTC: Vedanta Gets $5.4M for Antibiotic Resistance
1st Nov 20177:00 amRNSPRTC's Vedanta Licenses Microbiome IO Candidates
20th Oct 201712:07 pmRNSSecond Price Monitoring Extn
20th Oct 201712:02 pmRNSPrice Monitoring Extension
27th Sep 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
26th Sep 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
25th Sep 20177:00 amRNSResearch Update PRTC Gelesis Shows Efficacy/Safety
20th Sep 20177:00 amRNSPRTC Notes IP For Health Assessments from Speech
19th Sep 20177:00 amRNSPureTech Licenses Milk-Derived Exosome Technology
15th Sep 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
7th Sep 20175:00 pmRNSDirector/PDMR Shareholding
4th Sep 20177:00 amRNSDirector/PDMR Shareholding
31st Aug 20177:00 amRNSTotal Voting Rights
30th Aug 20177:00 amRNSPureTech Health plc Half-year Report
29th Aug 20177:00 amRNSPureTech Licenses Glyph Lymphatic Technology
25th Aug 20175:11 pmRNSAdditional Listing
2nd Aug 20177:00 amRNSNotice of Results
31st Jul 20177:00 amRNSDirector/PDMR Shareholding
13th Jul 20177:00 amRNSPureTech Presents Inflammation-Targeting Data
12th Jul 20177:00 amRNSPRTC's Gelesis Notes Last Patient in Pivotal Study
3rd Jul 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
28th Jun 20172:08 pmRNSPRTC's Akili Names Former Cubist CEO Exec Chairman
26th Jun 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Jun 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
13th Jun 20176:05 pmRNSHolding(s) in Company
13th Jun 20176:01 pmRNSHolding(s) in Company
9th Jun 20175:40 pmRNSPDMR DEALING - PURCHASE OF SHARES
7th Jun 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
31st May 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
30th May 20177:00 amRNSPureTech's Vedanta Granted New US Patent
25th May 20177:00 amRNSPureTech Health to Present at Jefferies Conference
23rd May 20177:01 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd May 20177:00 amRNSDirector/PDMR Shareholding
19th May 20177:00 amRNSPureTech's Karuna to Present at 2 Medical Meetings
17th May 20177:00 amRNSPureTech's Sync Project Announces New Investors
16th May 20177:00 amRNSPureTech's Vedanta Granted Three New US Patents
9th May 20175:00 pmRNSResult of AGM
9th May 20177:00 amRNSPureTech Initiates Phase 2b mTORC1 Study in RTIs
9th May 20177:00 amRNSAnnual Capital Markets Meeting
5th May 20177:00 amRNSPureTech Announces License for Microbiome Therapy
5th May 20177:00 amRNSPDMR DEALING - PURCHASE OF SHARES
3rd May 20172:00 pmRNSPureTech's Gelesis Receives Eur2.9 Million Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.